Ohsong passed a 2^nd-year support project in Jeju.

Ohsong Pharm passed the second-year evaluation of the development support business for Jeju local hidden champions, organized by Jeju Techno Park.

The evaluation, held annually by Jeju Techno Park, took place from May 9 to May 10. During this period, Ohsong Pharm’s first-year business results and second-year business plan were thoroughly deliberated.

During the first year of this project, Ohsong Pharm mainly focused on laying the foundation for the direct launch of medical drugs into Japan. The company collaborated with Brio Pharma, Ohsong Pharm’s Japanese local subsidiary, and acquired a manufacturing & sales business license in Japan. In the Korean domestic pharmaceutical industry, this marked the first instance of applying for approval of two new drug items from the Japanese PMDA.

As a result of the first year’s effort, Ohsong Pharm received a favorable evaluation, highlighting its export record and employment growth.

For the second year, from June 2019 to March 2020, Ohsong will focus on developing new items of CDMO and CMO for launch  in the Japanese market.

Ohsong and Brio will continue to work together, building on the support provided by Jeju.